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Available online 17 February 2016AbstractBackground: Small cell lung cancer (SCLC) is the most devastating type of human lung cancer. Patients usually present with disseminated
disease to many organs (extensive stage). This study was to investigate the efficacy and safety of cellular immunotherapy (CIT) with
autologous natural killer (NK), gdT, and cytokine-induced killer (CIK) cells as maintenance therapy for extensive-stage SCLC (ES-SCLC)
patients.
Methods: A pilot prospective cohort study was conducted with ES-SCLC patients who had responded to initial chemotherapy. Patients received
either CIT as maintenance therapy (CIT group), or no treatment (control group). Progression-free survival (PFS), overall survival (OS), and
adverse effects were compared.
Results: Forty-nine patients were recruited in this study, with 19 patients in the CIT group and 30 patients in the control group. The patient
characteristics of the 2 groups were comparable except for age, as patients in the CIT group were older than those in the control group
(P < 0.05). PFS in the CIT group was superior to the control group (5 vs. 3.1 months, P ¼ 0.020; HR, 0.489, 95% CI, 0.264e0.909, P ¼ 0.024).
OS of the CIT group was also longer than that of the control group (13.3 vs. 8.2 months, P ¼ 0.044; HR, 0.528, 95% CI, 0.280e0.996,
P ¼ 0.048, respectively). No significant adverse reactions occurred in patients undergoing CIT.
Conclusions: CIT maintenance therapy in ES-SCLC prolonged survival with only minimal side effects. Integrating CIT into the current
treatment may be a novel strategy for ES-SCLC patients, although further multi-center randomized trials are needed.
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Small cell lung cancer (SCLC) is the most devastative type
of human lung malignancies, with two-thirds of these patients
presenting with extensive disease. Despite a high initial
response rate to first-line chemotherapy, most patients die
rapidly from drug-resistant relapse. The median survival for
treated patients with extensive stage SCLC (ES-SCLC) is
8e13 months with modern chemotherapy, with 5% surviving
to 2 years and only 1% of patients achieving a long-term
disease-free survival [1]. Even with more advanced chemo-
therapeutic agents, the prognosis of this disease remains poor
due to low treatment efficacy [2,3]. Maintenance therapy has
recently become a treatment paradigm in advanced non-small
cell lung cancer (NSCLC) [4]. However, a meta-analysis of
published randomized clinical trials [5] showed that both
maintenance and consolidation therapy failed to improve the
outcomes of SCLC, and in some cases even caused severe side
effects or death. Thus, there is no recommendation for main-
tenance therapy in current SCLC treatment guidelines. Given
its high recurrence rate and mortality, new therapeutic strate-
gies are urgently needed to improve the outcome of this
disease.
Immune escape plays an important role in cancer recur-
rence and metastasis [6,7]. With an improved mechanistic
understanding of immune response and immune escape,
several immunotherapies were investigated for ES-SCLC.
Some of them failed, such as the dendritic cell-based p53
vaccine [8]. Some of them were effective, such as phased
ipilimumab (an antibody against cytotoxic T-lymphocyte
antigen-4 [CTLA-4]) with paclitaxel/carboplatin, pem-
brolizumab and nivolumab (an antibody against programmed
death-1 [PD-1]) for recurrent patients [9e11]. It indicated that
immunotherapy combined with chemotherapy might have the
potential to improve the prognosis of ES-SCLC. Therefore,
increasing attention has been paid to the development of
immunotherapy for ES-SCLC patients in recent years.
SCLC patients have often been found to have functional
deficiency in a variety of immunocytes [12e14], therefore
cellular immunotherapy (CIT) with ex vivo-activated and
expanded immunocytes may be feasible and effective in SCLC
patients. Several immunotherapies to induce cytotoxic T
lymphocyte (CTL) for SCLC have been tried. However few of
them have lengthened survival, partly due to the complexity of
the immune escape in this malignancy. Decreased expression
of HLA-class I antigen has been reported in SCLC, which may
be one of the mechanisms of SCLC cells to escape CTL attack
[15]. Natural killer (NK) and gdT cells are effector cells of
innate immunity, and both can exert anti-cancer effects in a
non-MHC-restricted manner. Cytokine-induced killer (CIK)
cells are ex vivo-activated lymphocytes, and represent a het-
erogeneous cell population, including CD3þCD56þ, which
show an NK-like, non-MHC-restricted cytolytic activity
against cancer cells. CIT based on one of these cell types has
proved to be effective against a variety of cancers [16e18],
and NK, gdT and CIK cells demonstrated synergistic cell-
killing effects when used in combination both in preclinicaland clinical studies [19e21]. SCLC cells were also found to
be susceptible to NK or gdT cell-mediated cytotoxicity in
preclinical studies [15,22]. In our previous small study, CIT as
maintenance therapy with the combination of NK, gdT and
CIK cells improved the outcome of SCLC patients, especially
in ES-SCLC patients with improved progression free survival
(PFS) and overall survival (OS) [23]. We therefore conducted
this study with more patients and longer follow-up time to
confirm the efficacy and safety of combined NK, gdT, and
CIK cells based CIT as maintenance therapy for ES-SCLC
patients who responded to first-line therapy.
2. Material and methods2.1. Patients and study designThis study was conducted in accordance with the Decla-
ration of Helsinki and was approved by the Ethical Committee
of the First Hospital of Jilin University [ID: 2009-020]. For
this prospective study, all patients with ES-SCLC that met the
following criteria at the First Hospital of Jilin University were
included from June 1, 2009. Written informed consent was
obtained from all patients before their enrollment into the
study.
Patients were eligible if they (i) had been diagnosed as ES-
SCLC and had completed first-line therapy, (ii) had achieved
stable disease (SD), partial remission (PR) or complete
remission (CR) after the first-line treatment, (iii) were at least
18 years old, (iv) had an Eastern Cooperative Oncology Group
(ECOG) performance status  2, (v) had normal kidney, liver,
and hematopoietic function and did not have cardiac ar-
rhythmias, congestive heart failure or severe coronary artery
disease, and (vi) had a life expectancy  3 months. Patients
were excluded if they (i) had autoimmune disease, (ii) had
serious infection, (iii) were women during pregnancy or
lactation, (iv) had a history of organ transplantation, and (v)
were receiving another immunotherapy.
The treatment regimens of ES-SCLC patients in this study
were based on the Small Cell Lung Cancer NCCN Guidelines
e version 2.2009 [24]. The first-line therapy regimen for ES-
SCLC patients was platinum based chemotherapy (EP regimen
or EC regimen) for 6 cycles plus radiotherapy to symptomatic
site [24].
After first-line therapy, patients received either CIT (at least
1 course) as maintenance treatment (CIT group), or no treat-
ment (control group). The decision whether to undergo CIT or
not was made by the patients. For the CIT group, autologous
peripheral blood mononuclear cells (PBMCs) were collected
by apheresis on D0, and were induced into NK, gdT, or CIK
cells. The expanded immunocytes were then infused back into
the patients 14 days later (D14) as the initial transfusion.
There were 6 consecutive transfusion days (D14eD20) with 2
types of immune cells for each infusion, and each CIT cycle
was completed within 3 weeks after apheresis. The second
cycle of PBMCs collection was started 1e3 weeks after the
end of the first course. The treatment schedule was described
in our previous report [23]. Maintenance treatment was
38 X. Ding et al. / Journal of Cellular Immunotherapy 2 (2016) 36e43continued unless there was progressive disease (PD) or the
patient refused to undergo further CIT. In cases of PD, the
patient was given either a best supportive treatment or a sec-
ond or even a third-line chemotherapy, depending on their
general health status and/or preference.
The second-line chemotherapy regimens were selected
based on the time of relapse. If patients experienced relapse
within 6 months after the first-line therapy, patients would be
treated with topotecan or irinotecan; if patients relapsed more
than 6 months after the completion of first-line therapy, they
would receive the original regimen. The third-line chemo-
therapy regimens were selected based on the previous
chemotherapy. Patients could be given irinotecan, topotecan or
paclitaxel that had not been used in the previous
chemotherapy.
Patients were followed up every 3 months. Each follow-up
included a complete physical examination, routine serum
chemistry, and computed tomography (CT) of the chest and
abdomen. Brain magnetic resonance imaging (MRI) and a
technetium bone scan were performed as clinically indicated.2.2. Preparation of immune cellsAll procedures for preparing the autologous immune cells
were carried out under Good Manufacturing Practice (GMP)
conditions (Certificate ID: A20090047) which were approved
by the Jilin Provincial Center for Sanitation Inspection and
Test. The preparation of and quality control for each type of
immunocytes was performed in strict accordance with the
standard operating procedure (SOP). Immune cells were pre-
pared as described in our previous reports [20,21,23]. Briefly,
PBMCs were collected from the patients using a Cobe Spectra
Apheresis System (Gambro BCT, Inc. USA). Lymphocytes
isolated from PBMCs by Ficoll-Hypaque density centrifuga-
tion (Amersham Biosciences, Uppsala, Sweden) were used to
induce NK, gdT and CIK cells using different cytokines.
Before transfusion, a fraction of cells was collected so that
they could be enumerated, evaluated for viability and pheno-
type, and checked for possible contamination.2.3. Phenotypic analysis of immunocytes before infusionThe phenotype of immunocytes was identified by using 4-
color flow cytometry performed on a FACSCalibur (BD Bio-
sciences, San Diego, CA, USA) with directly conjugated
mAbs. Briefly, cultured NK cells were collected, washed, and
incubated with mouse mAbs against human CD3-PerCP,
CD69-PE, and CD56-APC (BD Biosciences) for 15 min. The
gdT cells were incubated with Vg9-FITC and CD3-APC (BD
Biosciences), and the CIK cells were incubated with CD3-
PerCP, CD4-FITC, CD8-PE and CD56-APC (BD Bio-
sciences). Isotype-matched antibodies were used as controls.2.4. Administration of immune cellsDye-exclusion test was used to assess the viability of the
final cell suspension. Possible contamination of the immunecells was tested using a PCR-based assay for mycoplasma, as
well as assays for endotoxins, bacteria, and fungi, 24 h before
and on the day of administration. The immunocytes could not
be used for patients if they failed to meet the following
quality criteria: (i) a viability of more than 95%, (ii) no
contamination by bacteria, fungi, endotoxins, or mycoplasma
in either of the 2 assessments, (iii) at least 1.2e2.0  109 of
each type of cells per infusion; and (iv) more than 50% of the
cells had the NK (CD3CD56þ) or gdT (CD3þVg9þ)
phenotype, and more than 20% of cells had the CD3þCD56þ
CIK phenotype in NK, gdT and CIK cell culture system
respectively, as detected by flow cytometry. Before reinfu-
sion, immunocytes were washed 3 times with normal saline
and re-suspended in 50 mL of normal saline. The cells were
then administered to patients intravenously in 30 min. The
number of cells in each transfusion ranged from 2.4 to
4.0  109.2.5. Clinical assessmentEfficacy was determined based on the National Cancer
Institute's Response Evaluation Criteria in Solid Tumors
(RECIST 1.1) guidelines [25]. The primary objective was
OS, defined as the period from the day on which first-line
treatment was completed to death from any cause. The sec-
ondary end points included PFS, safety of CIT and clinical
benefit rate (CBR) of the second-line chemotherapy. PFS was
defined as the period between the completion of first-line
treatment and the onset of PD or death from any cause.
CBR was defined as the percentage of patients with
CR þ PR þ SD.2.6. Statistical methodsResults were analyzed with the SPSS 17.0 software (SPSS,
Chicago, IL). PFS and OS were assessed according to the
KaplaneMeier method and compared between groups using
the log-rank test. The multivariate Cox proportional hazard
model was applied to analyze factors found to be statistically
significant by univariate analysis. The ManneWhitney test
was used to compare medians, and Fisher's exact test was used
to compare binary outcomes. P  0.05 was considered to be
statistically significant.
3. Results3.1. Patient characteristicsA total of 49 eligible patients were recruited in this study,
with 19 patients in the CIT group and 30 patients in the control
group. The patient demographics were well balanced between
the groups, including sex, smoking index, ECOG performance
status, chemotherapy course, radiotherapy and response to
induction chemotherapy (Table 1). The only exception was
age, as patients in the CIT group were on average older than
those in the control group (P < 0.05).
Table 1
Clinical characteristics of patients in the CIT and control groups.
Clinical features CIT group Control group P-value
Sex
Male 18 22 0.127
Female 1 8
Age, years
Median (range) 63 (54e79) 57 (36e74) 0.002
Smoking index
Median (range) 400 (0e1200) 400 (0e2000) 0.983
ECOG






Yes 7 17 0.176
No 12 13
RT to symptomatic sites
Yes 7 12 0.825
No 12 18
PCI
Yes 2 1 0.551
No 17 29
Response to induction chemotherapy
CR þ PR 14 22 0.978
SD 5 8
Abbreviations: CIT, cellular immunotherapy, ECOG, Eastern Cooperative
Oncology Group; RT, radiotherapy; PCI, prophylactic cranial radiation; CR,
complete remission; PR, partial remission, SD, stable disease.
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system was found to exceed 95%, none of the cultured im-
mune cells were found to be contaminated, and all of the
preparations met the quality criteria. The percentage of NK
(CD3CD56þ), gdT (CD3þVg9þ) and CIK (CD3þCD56þ)
cells before and after induction was 8.35% (range,
3.97e18.42%) vs. 82.56% (range, 58.33e99.61%), 4.78%
(range, 2.34e12.35%) vs. 80.63% (range, 55.72e98.21%) and
4.51% (range, 1.55e8.45%) vs. 34.52% (range,
26.65e58.23%), respectively (Table 2). Induction also resul-
ted in a significant increase in the proportion of activated NK
cells (CD56þCD69þ). Representative results from a single
patient are shown in Fig. 1.3.3. PFS and OSFollow-up of all patients was ended on December, 2015,
with a median follow-up time of 10.3 months (range, 3e55.2Table 2
Summarized data of the percentage of NK, gdT and CIK cells before and after
induction.
Immune cells Before (median, range) After (median, range)
NK cells 8.35% (3.97e18.42%) 82.56% (58.33e99.61%)
gdT cells 4.78% (2.34e12.35%) 80.63% (55.72e98.21%)
CIK cells 4.51% (1.55e8.45%) 34.52% (26.65e58.23%)
Abbreviations: NK, natural killer; CIK, cytokine-induced killer.months). PFS in the CIT group was superior to the control
group (5 vs. 3.1 months, P ¼ 0.020) (Fig. 2A), and CIT as
maintenance therapy significantly reduced the risk of ES-
SCLC recurrence (hazard ratio [HR], 0.489, 95% confidence
interval [CI], 0.264e0.909, P ¼ 0.024). OS of the CIT group
was also longer than that of the control group (13.3 vs. 8.2
months, P ¼ 0.044; HR, 0.528, 95% CI, 0.280e0.996,
P ¼ 0.048, respectively) (Fig. 2B). The 1-year and 2-year OS
rate of the CIT and control group was 57.9% vs. 40.0% and
15% vs. 3.6%, respectively.3.4. Potential factors influencing the outcome of CITIn the multivariate analysis, we found that sex, age,
smoking index, ECOG performance status, chemotherapy
course, radiotherapy and response to induction chemotherapy
had no effect on the prognosis of ES-SCLC patients receiving
CIT (P > 0.05), but the CIT course had an effect both on the
PFS and OS of CIT patients (P < 0.05). We then investigated
the influence of the CIT course on the prognosis of patients in
the CIT group. The median number of CIT cycles was 3
(range, 1e6 cycles). Patients were divided into two subgroups:
long-course group with CIT 3 cycles and short-course group
with CIT <3 cycles. The characteristics of the patients in these
subgroups were well balanced (Table 3). The median PFS in
the long-course group (n ¼ 11) was longer than that of the
short-course group (n ¼ 8) (5.2 vs. 2.2 months, P ¼ 0.009;
HR, 0.276; 95% CI, 0.098e0.779; P ¼ 0.015) (Fig. 3A). The
median OS of the long-course group was also significantly
longer than that of the short-course group (20.1 vs. 6.7 months,
P ¼ 0.005; HR, 0.217, 95% CI, 0.069e0.687, P ¼ 0.009)
(Fig. 3B).3.5. Response to second-line chemotherapyA total of 14 patients accepted second-line therapy in the
CIT group, and 15 patients received second-line therapy in the
control group. The median second-line chemotherapy courses
were 2 (range, 1e6) for both groups (P > 0.05). None of the
patients in the two groups achieved CR after second-line
treatment. Eight patients got a PR or SD with a CBR of
57.1% in the CIT group, and 7 patients got a PR or SD with a
CBR of 46.7% in the control group, but there was no signif-
icant difference between the groups (P ¼ 0.573).3.6. Side effects of CITTwo patients had a transient fever after CIT infusion, but
recovered within 2 h after administration of antipyretics or
physical cooling. Three patients reported mild fatigue after
CIT infusion. No other significant side effects were observed.
4. Discussion
ES-SCLC is a disease with poor prognosis. Treatment
outcome has not improved significantly during the last decades
despite great efforts have been made. Maintenance therapy has
Fig. 1. The percentage of NK, gdTand CIK cells before and after induction. Representative results from a single patient are shown. The percentage of NK cells
(A), gdT cells (B) and CIK cells (C) before and after induction was 14.4% vs. 95.3%, 3.47% vs. 98.1% and 1.88% vs. 47.2%, respectively. CD56þCD69þ cells
were considered to be activated NK cells.
Fig. 2. Progression free survival (PFS) and overall survival (OS) in both groups. (A) PFS of the two groups. PFS in the CIT group was longer than the control
group (5 vs. 3.1 months, P ¼ 0.020). (B) OS of the two groups. OS in the CIT group was significantly longer than in the control group (13.3 vs. 8.2 months,
P ¼ 0.044).
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onset of recurrence and prolong survival. However, mainte-
nance and/or consolidation using chemotherapy, cytokines and
other biological agents failed to improve ES-SCLC outcomes
[5]. Molecularly targeted drugs have been used as mainte-
nance therapy in ES-SCLC in recent years, but most of them
did not improve the OS of ES-SCLC patients, such as sor-
afenib, vandetanib, and imatinib [26e28]. Therefore, new
therapeutic strategies are urgently needed to improve the
outcome of this disease.
Immune escape in SCLC patients is closely associated with
the recurrence of the disease, and may contribute to poor pa-
tient survival [6,7,12e14]. Cancer cells employ multiple
mechanisms to evade an immune response [29e31], and thus
CIT with only one type of immune cells is unlikely to achieve
an optimal anticancer effect. In our previous study, CIT as
maintenance therapy with the combination of NK, gdT and
CIK cells has exhibited a synergistic anticancer effect andimproved the outcome of SCLC patients, especially in ES-
SCLC patients. The present study, with more patients
enrolled and longer follow-up time, further confirmed the ef-
ficacy and safety of combined CIT as maintenance therapy for
ES-SCLC patients. Thus, CIT may be a novel treatment for
ES-SCLC patients who respond to first-line therapy, and can
provide a novel strategy for the devastating disease.
ES-SCLC is a highly malignant tumor associated with short
survival and limited chemotherapy regimens, and hence there
are fewer confounding factors for OS. In our study, OS was
significantly longer after CIT in ES-SCLC patients. There are
several possible reasons for the prolonged survival observed.
Cancer stem cells (CSCs) have been reported to be responsible
for cancer progression, metastasis, and the development of
drug resistance [32,33]. They have also been shown to be
susceptible to immunocyte-mediated toxicity, suggesting that
CIT may be useful in eliminating minimal residual disease and
thus reduce cancer recurrence [34e36]. Prolonged PFS and
Table 3
Clinical characteristics of patients in two subgroups.
Clinical features Long-course Short-course P-value
Sex
Male 11 7 0.421
Female 0 1
Age, years
Median (range) 63 (54e79) 66.5 (58e78) 0.422
Smoking index
Median (range) 600 (0e1000) 150 (0e1200) 0.424
ECOG






Yes 4 3 1.000
No 7 5
RT to symptomatic sites
Yes 3 4 0.377
No 8 4
PCI
Yes 2 0 0.485
No 9 8
Response to induction chemotherapy
CR þ PR 8 6 1.000
SD 3 2
Abbreviations: ECOG, Eastern Cooperative Oncology Group; RT, radio-
therapy; PCI, prophylactic cranial radiation; CR, complete remission; PR,
partial remission, SD, stable disease.
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for longer OS of ES-SCLC patients in the CIT group. But one
study exploring the relationship between PFS and OS in SCLC
patients found no significant relationship between them [37],
suggesting that OS might be affected by other factors, such as
second or third-line therapy.
It has been reported that patients who received cancer
vaccines responded better to subsequent chemotherapy than
those who did not, suggesting that immunotherapy might
sensitize cancer cells to cytotoxic drugs [38,39]. Indeed, pa-
tients with CIT tended to have higher CBR than the control in
our study, although the difference was not significant,Fig. 3. The influence of cellular immunotherapy (CIT) course on extensive sta
progression free survival (PFS) in the long-course group was longer than that of th
survival (OS) in the long-course group was significantly longer than that of patienindicating that CIT might enhance the sensitivity of recurrent
SCLC to second-line chemotherapy. It is noteworthy that only
half of the patients in the control group received second-line
chemotherapy, but most of the patients in the CIT group
received second-line chemotherapy. The main reason why half
of the patients in the control group didn't receive second-line
chemotherapy was the low performance status. Only a very
small number of patients didn't receive second-line chemo-
therapy because they refused further treatment. Therefore, CIT
might improve the quality of life of cancer patients, so that
more patients have the opportunity to receive second-line
chemotherapy after CIT maintenance therapy. This might be
another reason that CIT could prolong OS. The underlying
mechanism needs to be further explored.
Potential factors influencing the outcome of CIT were also
evaluated in this study. Using a multivariate analysis, we found
that sex, age, smoking history, ECOG performance status,
chemotherapy course, radiotherapy and response to induction
chemotherapy were not related to the efficacy of treatment.
Patients receiving longer CIT course had longer PFS and OS.
Both PFS and OS in patients who received more than 3 cycles
of CIT was significantly longer than that of patients who
received less than 3 cycles of CIT. OS was consistent with our
previous report. In our previous study, PFS tended to be longer
in patients who received more than 3 CIT cycles, but the
different was not statistically significant. The difference be-
tween the two studies may be due to the different sample size
and follow-up time. Besides, some patients with early stage
SCLC were included in the previous study. One study
demonstrated that NSCLC patients who received more than 7
cycles of CIK cell treatment had a significantly better prog-
nosis than those who received fewer cycles [40]. Taken
together, our findings and those of a previous report [40]
suggest that a longer CIT course improved patient outcome.
However, the optimal number of treatment cycle and the
length of treatment course are yet to be determined. Even
though the characteristics of the patients in these subgroups
were well balanced, some patients stopped CIT treatment in
the short course group because of disease progression.
Therefore, the shorter PFS and OS might be affected not onlyge small cell lung cancer (ES-SCLC) patients' prognosis. (A) The median
e short-course group (5.2 vs. 2.2 months, P ¼ 0.009). (B) The median overall
ts in the short-course group (20.1 vs. 6.7 months, P ¼ 0.005).
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worse disease status in this subgroup of patients.
Safety is an important factor determining the application of
CIT. In this study, only 3 patients reported mild fatigue and 2
patients had a transient fever after infusion. All symptoms
diminished after treatment. We did not observe any significant
side effects after CIT. Thus, CIT was well tolerated and is a
good candidate for maintenance therapy when side effects
need to be minimized.
To assess of the impact of CIT on the immune system, we
compared the number of immune cells (T, NK, NKT, B, Treg
cells and monocytes) in the peripheral blood before and after
CIT and did not find any significant change. There were
relatively fewer Treg cells at some time points after CIT, but
these differences were not significant. This might reflect the
relatively few CIT courses and the small number of patients
involved. However, this might indicate that response to CIT is
not associated with the proportion of immune cells in the
peripheral blood and this needs to be addressed in the further
studies. This also reflects the challenge to find markers for
assessing immune response.
In our study, ES-SCLC patients in the CIT group were on
average older than those in the control group. However, the
multivariate analysis showed that age had no effect on the
prognosis of these patients. Therefore, age was no a con-
founding factor, although it has been reported that effector cell
function decreases in older people, and might be associated
with reduced antitumor immunity in these patients [41].
One limitation of this study is that patients were allocated
to each group according to the patients' therapeutic options.
Further multi-center randomized clinical trials are needed to
verify its efficacy.
5. Conclusions
CIT as a maintenance therapy after first-line treatment
might prevent disease recurrence and prolong the survival of
ES-SCLC patients with only minimal side effects. We also
found that more CIT courses might improve treatment
outcome. CIT might enhance the sensitivity of recurrent ES-
SCLC to second-line chemotherapy. The exact mechanism
through which CIT extends PFS and OS in ES-SCLC patients
remains to be explored.
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